<DOC>
	<DOCNO>NCT00582582</DOCNO>
	<brief_summary>The purpose research study find toxicity doxercalciferol give combination docetaxel ( TaxotereÂ® ) , well see well combination work treatment prostate cancer .</brief_summary>
	<brief_title>Study Docetaxel With Doxercalciferol Placebo Advanced Prostate Cancer</brief_title>
	<detailed_description>This multi-institutional , double-blinded , randomize study compare docetaxel plus doxercalciferol versus docetaxel plus placebo patient metastatic hormone refractory prostate cancer . Docetaxel give intravenously day 1 , 8 15 every 28 day cycle doxercalciferol placebo take orally every day 28 day cycle . Please refer Eligibility Criteria key inclusion exclusion criterion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Histologic diagnosis adenocarcinoma prostate . evidence metastatic disease within 4 week registration . Must meet ONE follow : 1 . PSA &gt; or= 10 ng/mL least one lesion bone scan . 2 . Soft tissue metastasis and/or visceral disease per CT scan . Must show progress prostate cancer see one follow : 1 . At least one new lesion bone scan , 2 . Increase size number measurable disease lesion , 3 . At least 2 rise PSA measurement least two week apart . Prior bilateral orchiectomy LHRH agonist therapy serum testosterone level &lt; 50 . Must flutamide , nilutamide , ketoconazole herbal supplement use treat prostate cancer least 4 week prior registration bicalutamide least 6 week prior registration . No prior cytotoxic chemotherapy . WHO performance status 02 . Peripheral neuropathy must &lt; = grade 1 . A history radiographically confirm kidney stone pathologically confirm calcium stone within last 10 year . Patients continue take bisphosphonates study long bisphosphonate start least 4 week prior study entry patient continue demonstrate rise PSA No prior treatment suramin , strontium therapeutic radioisotope . No radiotherapy within past 4 week . No known brain metastasis . No chronic hypercalcemia ( serum calcium &gt; 1.0 mg/dl upper limit normal range ) , chronic gastrointestinal disease ( malabsorption , surgery affect absorption , chronic ulcerative colitis ) condition investigator feel would put patient undue risk . Must take digitalis , thiazide diuretic ( drug combination thiazide ) calcium supplement within one week treatment initiation . No active angina , know heart disease New York Heart Association Class IIIV recent history ( &lt; 6 month ) myocardial infarction . Must take steroid , anticonvulsant , fluoride , lithium . Must urinary protein &gt; 4gm/24 hour Must urinary calcium &gt; or= 500 mg/24 hour No Coexistent second malignancy history prior malignancy within previous 5 year ( exclude basal squamous cell carcinoma skin treat curatively ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Hormone Refractory</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>